WuXi Biologics (Cayman) Inc. ADR logo

WuXi Biologics (Cayman) Inc. ADR (1FW1)

Market Closed
10 Aug, 20:00
XFRA XFRA
10. 20
+0.3
+3.0303%
14.36B Market Cap
15.48 P/E Ratio
- Div Yield
114 Volume
0 Eps
9.9
Previous Close
Add Transaction
Day Range
9.95 10.2
Year Range
6.3 10.2
Want to track 1FW1 and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!

Summary

1FW1 closed today higher at €10.2, an increase of 3.0303% from yesterday's close, completing a monthly increase of 34.2105% or €2.6. Over the past 12 months, 1FW1 stock gained 46.7626%.
1FW1 is not paying dividends to its shareholders.
The last earnings report, released on Mar 23, 2026, exceeded the consensus estimates by 0%. On average, the company has surpassed earnings expectations by 0%, based on the last three reports.
WuXi Biologics (Cayman) Inc. ADR has completed 1 stock splits, with the recent split occurring on Dec 10, 2020.
The company's stock is traded on 4 different exchanges and in various currencies, with the primary listing on OTC PINK (USD).

1FW1 Chart

People also search for

Amgen Inc. Canadian Depositary Receipt
18.7
+2.7473%
Gilead Sciences Inc. Canadian Depositary Receipt
16.5
+1.8519%
Abbott Laboratories CDR
11.6
+0.8696%
Novo Nordisk A/S
11.7
+0.8621%
Pfizer Inc.
6.1
+2.521%
WuXi Biologics (Cayman) Inc. (WXXWY) Q4 2025 Earnings Call Transcript

WuXi Biologics (Cayman) Inc. (WXXWY) Q4 2025 Earnings Call Transcript

WuXi Biologics (Cayman) Inc. (WXXWY) Q4 2025 Earnings Call Transcript

Seekingalpha | 4 months ago
WuXi Biologics (Cayman) Inc. (WXXWY) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

WuXi Biologics (Cayman) Inc. (WXXWY) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

WuXi Biologics (Cayman) Inc. (WXXWY) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Seekingalpha | 6 months ago
WuXi Biologics: Spotlight On Property Disposal And Operating Metrics (Rating Upgrade)

WuXi Biologics: Spotlight On Property Disposal And Operating Metrics (Rating Upgrade)

My rating upgrade for WuXi Biologics to a Buy has taken into consideration its latest corporate move and business disclosures. The sale of its European manufacturing facility will throw up margin improvement and capital allocation opportunities for WXXWY. The company has secured new projects and new customers from markets outside its home market despite geopolitical concerns.

Seekingalpha | 1 year ago

WuXi Biologics (Cayman) Inc. ADR (1FW1) FAQ

What is the stock price today?

The current price is €10.20.

On which exchange is it traded?

WuXi Biologics (Cayman) Inc. ADR is listed on XFRA.

What is its stock symbol?

The ticker symbol is 1FW1.

Does it pay dividends? What is the current yield?

It does not pay dividends to its shareholders.

What is its market cap?

As of today, the market cap is 14.36B.

Has WuXi Biologics (Cayman) Inc. ADR ever had a stock split?

WuXi Biologics (Cayman) Inc. ADR had 1 splits and the recent split was on Dec 10, 2020.

WuXi Biologics (Cayman) Inc. ADR Profile

Biotechnology Industry
Healthcare Sector
Zhisheng Chen CEO
XFRA Exchange
98260N108 CUSIP
CN Country
13,252 Employees
- Last Dividend
10 Dec 2020 Last Split
- IPO Date

Overview

WuXi Biologics (Cayman) Inc. is a prominent global company deeply embedded in the biopharmaceutical sector, offering comprehensive end-to-end solutions that encompass the entire lifecycle of biologics, including discovery, development, and manufacturing. Established in 2014 and based in Wuxi, China, the company operates not only within the People's Republic of China but also extends its outreach to North America, Europe, and various international markets. WuXi Biologics specializes in a wide array of services ranging from biopharmaceutical technology consultation to international sales contracting, testing development, marketing, clinical and manufacturing services in the biologics field. Additionally, it is invested in the production and sale of medicals, including engaging in vaccine contract development and manufacturing organization (CDMO) operations and supplying materials related to its core activities. Highlighting its commitment to innovation, the company is in partnership with BioNTech SE, under a research service agreement, to explore and identify monoclonal antibodies for the development of advanced therapeutic product candidates, showcasing its pivotal role in the future of biopharmaceuticals.

Products and Services

  • Biopharmaceutical Technology Consultation: WuXi Biologics provides expert advice and consultation services for biopharmaceutical companies seeking to innovate and improve their drug discovery and development processes. This includes strategic planning, process optimization, and regulatory compliance support to ensure success in the competitive biologics market.
  • International Sales Contracting Services: The company facilitates global market access for biopharmaceutical products through seasoned international sales and contracting services, catering to organizations aiming to expand their reach beyond local markets.
  • Testing and Development of Testing Technologies: WuXi Biologics offers cutting-edge testing services and the development of new testing technologies. This encompasses a comprehensive range of analytical methods and procedures designed to ensure the safety, efficacy, and quality of biopharmaceuticals throughout the product lifecycle.
  • Sales and Marketing Services: Leveraging its global presence, WuXi Biologics also provides sales and marketing services tailored to the biopharmaceutical sector. These services aim to maximize product visibility, market share, and profitability through strategic marketing plans and execution.
  • Biologics Clinical and Manufacturing Services: At its core, WuXi Biologics specializes in offering clinical and manufacturing services for biologics. This includes cGMP-compliant manufacturing facilities, process development capabilities, and clinical trial support designed to streamline the path from discovery to commercialization.
  • Production and Sale of Medicals: The company is involved in the production and sale of various medical products, contributing to healthcare and treatment protocols globally. This includes a range of biopharmaceutical products manufactured under stringent quality control standards.
  • Vaccine Contract Development and Manufacturing Organization (CDMO): WuXi Biologics provides comprehensive CDMO services specifically for vaccines, covering all stages from vaccine development to manufacturing. This addresses the growing demand for vaccines and immunotherapeutic products in global healthcare.
  • Material Supplier Activities: Supporting its main operations, the company also acts as a material supplier, providing critical raw materials and components necessary for biopharmaceutical research, development, and manufacturing processes.

Contact Information

Address: No. 108, Meiliang Road
Phone: +86 510 8183 5000